Selenium supplementation may increase the efficacy of cetuximab in metastatic colorectal cancer patients

Medical Hypotheses

Volumn 64, Issue 6, 2005, Pages 1162-1165

  Altundag, Kadri ^a   Silay, Yavuz S ^b   Altundag, Ozden ^c   Yigitbasi, Orhan G ^d   Gundeslioglu, Ozlem ^e   Gunduz, Mehmet ^f  

^a HACETTEPE UNIVERSITY   (Turkey)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c School of Medicine ^*  (United States)

^d ERCIYES UNIVERSITY   (Turkey)

^e BASKENT UNIVERSITY   (Turkey)

^f OKAYAMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CETUXIMAB; CHIMERIC PROTEIN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FLUOROURACIL; FOLINIC ACID; IMMUNOGLOBULIN G1 ANTIBODY; IRINOTECAN; LIGAND; LIPID; NONSTEROID ANTIINFLAMMATORY AGENT; OXALIPLATIN; PROSTAGLANDIN E2; SELENIUM; SELENOMETHIONINE;

ADVANCED CANCER; CANCER CELL; CANCER PATIENT; CARCINOGENESIS; CLINICAL TRIAL; COLORECTAL CANCER; DRUG ACTIVITY; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SPECIFICITY; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; REFRACTORY PERIOD; REVIEW; SKIN METASTASIS; SUPPLEMENTATION;

EID: 17044427543     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2004.11.041     Document Type: Article

References (17)

1. R.N. DuBois, F.M. Giardiello, and W.E. Smalley Nonsteroidal anti-inflammatory drugs, eicosanoids, and colorectal cancer prevention Gastroenterol Clin North Am 25 1996 773 791
2. C.E. Eberhart, R.J. Coffey, A. Radhika, F.M. Giardiello, S. Ferrenbach, and R.N. DuBois Up-regulation of COX 2 gene expression in human colorectal adenomas and adenocarcinomas Gastroenterology 107 1994 1183 1188
3. F.A. Sinicrope, M. Lemoine, L. Xi, P.M. Lynch, K.R. Cleary, and Y. Shen Reduced expression of cyclooxygenase 2 proteins in hereditary nonpolyposis colorectal cancers relative to sporadic cancers Gastroenterology 117 1999 350 358
4. A. Diaz, K.P. Chepenik, J.H. Korn, A.M. Reginato, and S.A. Jimenez Differential regulation of cyclooxygenases 1 and 2 by interleukin-1 beta, tumor necrosis factor-alpha, and transforming growth factor-beta 1 in human lung fibroblasts Exp Cell Res 241 1988 222 229
5. R.A. Gupta, L.V. Tejada, B.J. Tong, S.K. Das, J.D. Morrow, and S.K. Dey Cyclooxygenase-1 is overexpressed and promotes angiogenic growth factor production in ovarian cancer Cancer Res 63 2003 906 911
6. H. Sheng, J. Shao, M.K. Washington, and R.N. DuBois Prostaglandin E2 increases growth and motility of colorectal carcinoma cells J Biol Chem 276 2001 18075 18081
7. F.G. Buchanan, D. Wang, F. Bargiacchi, and R.N. DuBois Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor J Biol Chem 278 2003 35451 35457
8. H.S. Samaha, R. Hamid, K. el-Bayoumy, C.V. Rao, and B.S. Reddy The role of apoptosis in the modulation of colon carcinogenesis by dietary fat and by the organoselenium compound 1,4-phenylenebis (methylene) selenocyanate Cancer Epidemiol Biomarkers Prev 6 1997 699 704
9. G.F. Combs Jr., and W.P. Gray Chemopreventive agents: selenium Pharmacol Ther 79 1998 179 192
10. R.C. McKenzie, T.S. Rafferty, and G.J. Beckett Selenium: an essential element for immune function Immunol Today 19 1998 342 345
11. L.C. Clark, G.F. Combs Jr., B.W. Turnbull, E.H. Slate, D.K. Chalker, and J. Chow Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional prevention of cancer study group JAMA 276 1996 1957 1963
12. S. Giacchetti, B. Perpoint, R. Zidani, N. Le Bail, R. Faggiuolo, and C. Focan Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer J Clin Oncol 18 2000 136 147
13. L.B. Saltz, J.V. Cox, C. Blanke, L.S. Rosen, L. Fehrenbacher, and M.J. Moore Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer New Engl J Med 343 2000 905 914
14. I. Porebska, A. Harlozinska, and T. Bojarowski Expression of the tyrosine kinase activity growth factor receptors (EGFR, ERB B2, ERB B3) in colorectal adenocarcinomas and adenomas Tumour Biol 21 2000 105 115
15. N.S. Goldstein, and M. Armin Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: implications for a standardized scoring system Cancer 92 2001 1331 1346
16. L.N. Klapper, M.H. Kirschbaum, M. Sela, and Y. Yarden Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors Adv Cancer Res 77 2000 25 79
17. D. Cunningham, Y. Humblet, S. Siena, D. Khayat, H. Bleiberg, and A. Santoro Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer New Engl J Med 351 2004 337 345